Nieves Martinez Lago MD PhD· @DraMartinezLago · X·· 2 days agoScore90
Body · original
#ESMO26 🧬 G-HOPE-001 | Phase III
👥 460 pts | CLDN18.2+ G/GEJA, ≥3L
💊 Arcotatug tavatecan (ADC) vs TPC
📈 PFS: 7.1 vs 3.1 mo (HR 0.45; updated)
⏳ OS: 10.2 vs 6.9 mo (HR 0.57; p<0.0001)
🎯 ORR: 37.4% vs 7.7%
🚀 Significant PFS & OS benefit!
@OncoAlert
4060 views · 17 likes · 12 reposts · 0 replies
Conference abstracts
LBA77matched by Proffered paper 1: Gastrointestinal tumour, upper digestive
Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G
https://esmocongress.esmo.orgSource: Nieves Martinez Lago MD PhD · x.com